Pharma: Code won't impede grants

Share this article:
A recently passed report by the AMA's Council on Ethical and Judicial Affairs (CEJA) won't have a significant effect on commercial funding for CME, pharma companies said.
“While we don't expect there to be any significant changes in the way commercial support is requested, offered or managed moving forward, these new ethical guidelines should help to encourage other stakeholders (academia, government, payers and health systems) to assume a greater responsibility in the financial support of CME,” Maureen Doyle-Scharff, senior director, team lead, in Pfizer's medical education group, told MM&M. “This will be good for CME, healthcare professionals and patients.”
Pamela Mason, director of the med ed grants office at AstraZeneca, concurred: “I do not expect that the CEJA recommendations will have a negative impact on industry funding of independent medical education...This is an important statement by CEJA and goes to the heart of why industry supports independent medical education.”
The report advises physicians who participate in CME to “strive to avoid” financial ties with industry, where possible. It was the fifth version to come before AMA's House of Delegates.
The Alliance for CME testified against passage, saying the CEJA recommendations were not based on objective data and that current rules were adequate to prevent bias.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?